This report summarise research evaluating the main legal barriers to the better use of health data for pharmaceutical innovation. Issues are evaluated according to barriers arising in utilising data to support key activities across the lifecycle of a medicine: epidemiology
This case study outlines the process undertaken by Public Health England (PHE) to establish the central WGS service. It also outlines the transformation of a national bacteriology reference laboratory into a genomics-led service. This includes: changes in workflows working practices and revisions to
Genomics is the study of a person’s entire DNA sequence. It has the potential to transform medical care and improve patient outcomes across the world and in the NHS. This response to the House of Commons Science and Technology Committee’s
Genomics has the potential to transform medical care across the world and in the NHS as well as dramatically improve patient outcomes in the UK and globally. The UK is considered to be a world leader in the development of Genomics. The
Review of how the workforce needed to be prepared to work with new technologies. The interim report proposes three key themes and three guiding principles and calls for evidence to inform the final report. Themes: Genomics Digital Medicine AI and
Outlines the key issues arising from an evidence session which was held to explore whether and how the NDG might help to address concerns about the legitimacy of genomic data sharing within the NHS for direct care and routine service delivery.
Annual CMO report that looks at genomics, exploring how they are currently utilises the health and care system and how its potential may be developed. Topics covered include the care and treatment of cancer, diagnosing rare diseases, the use of genomics in screening and ‘personalised’ prevention,